Pfizer Inc. (NYSE:PFE) Shares Purchased by Lazari Capital Management Inc.

Lazari Capital Management Inc. increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 45.0% during the 4th quarter, Holdings Channel.com reports. The fund owned 32,229 shares of the biopharmaceutical company’s stock after buying an additional 10,005 shares during the period. Lazari Capital Management Inc.’s holdings in Pfizer were worth $855,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $26,000. Gladius Capital Management LP increased its stake in shares of Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 38,015 shares during the period. Quarry LP acquired a new stake in shares of Pfizer in the second quarter valued at approximately $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in shares of Pfizer in the third quarter valued at approximately $35,000. Finally, Joseph Group Capital Management increased its stake in shares of Pfizer by 168.3% in the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 771 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Down 1.5 %

Pfizer stock opened at $26.51 on Monday. The firm has a 50 day moving average price of $26.27 and a two-hundred day moving average price of $27.85. The firm has a market cap of $150.20 billion, a price-to-earnings ratio of 35.82, a PEG ratio of 0.66 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.49%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s payout ratio is currently 232.44%.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of research analyst reports. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. Guggenheim reduced their target price on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Sanford C. Bernstein assumed coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price for the company. Finally, Wolfe Research assumed coverage on shares of Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 target price for the company. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.